U.S. Markets closed

Omeros Corporation (OMER)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
25.71-0.85 (-3.20%)
At close: 4:00PM EDT
People also watch
  • Today all the Russell Indxes have to readjust their stocks. This intern means a lot of mutual funds have to update their holdings since OMER is now in the Russell 2000 we could see some volatility in our stock. Let's hope it's UP!
  • That GD, young amateur guy was bashing PTLA along with OMER. I should have bought a ton PTLA based on his stupidity alone.
  • If you have a chance to turn $1 into $10 with a 50% chance, are you going to bet on it? No-brainer, isn't? Here the actual chance is more than 50% with breakthrough designation. Hold and you will be rewarded !
  • Healthy consolidation, no reason to panic. had to happen sooner or later, should be a relief. $30+ by end of next week. higher if OMER has good news come out
  • Nice range and recovery! Now will Dr D announce partnership before end of July?
  • Omeros Is Gaining Momentum With A Diverse Pipeline Summary

    •Omeros has one of the most diverse pipelines for a junior biotech out there at present, giving it multiple potential areas for success.

    •Omidria is gaining sales year over year and has lots of room to grow ahead of it, giving Omeros a potential positive cash flow generating product to fund pipeline development.

    •OMS721, the furthest advanced pipeline candidate, continues to show promise and if approved, can unlock significant value for the company and its shareholders in the near future.
    Omeros Corporation (NASDAQ:OMER) is a junior biotech with big goals, and a large portfolio of drug candidates, that's already generating growing revenues as it looks to fund the development of its potential blockbuster treatments. With 12 programs under development (both clinical and pre clinical), there's a lot of potential here, and the share price has been climbing to near all time highs on the back of recent positive developments. That being said, this might just be the beginning of what could turn out to be a company with significant revenue generating ability in the next few years.
  • BUY THE DIP! 👍🏼👍🏼 THIS STOCK IS GOING TO 50 easily
  • Been in this since it was 6$ and some change. Rode it up and down through the last big bump but took a little profit to replace my car with a new one before it dropped below 25. Got back in with more when it went below 10 and here we are right back up. But!! this time there is a whole new ball game with FDA's status verifying 701 not only works but is a breakthrough. No more selling for me now. At least till I retire or maybe when it breaks $100 then I might have to take a little off the top to celebrate. I am in for the long haul now.
  • I know it couldn't gain forever, but should we see a close of $26.60? Hold your shares
  • Some day Longs
    OMER will make move like CLVS and now PTLA.
  • There is absatootly zero doubt that OMER has had a terrific run this year since January.
    Congrats to all the longs!!!
    My questions are - Is anyone concerned about Alexion??? Is anyone betting on both companies ???
    Alexion snagged a fantastic asset (Paul Clancy) away from Biogen and the CEO just bought a ton of their stock.

    I am ultra long in OMER, and at this point I am considering starting a position in Alexion.
    Thoughts please.........................
  • OMER sues Sandos..

    Omeros Corp. (OMER) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on June 16, 2017.

    On June 21, 2017, Omeros filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware and a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Sandoz Inc., or Sandoz, and on June 22, 2017, Omeros filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware and a patent infringement lawsuit in the U.S.
  • Making a comeback.
  • The shorts are going to get squeezed painfully. This is investors taking profits before the weekend and shorters in the works of trying to bring this very valuable company down a tad. Don't let the short squeeze hit you on the way up. There is still a lot to cover.
  • Incidence of IgA nephropathy in USA 75-100k per year. In eu it is 150k to 200k per year. In Asian it is three times more in incidence rate in Japan and other countries. At 250k per pop you have crazy revenue per year with new cases. Why would anyone sell st this price or anything less than 300?
  • Not liking the volume on this sharp decline
  • What a turn around! If this closes near $27 the shorts will lose big time and I don t see how they are hedging this unless they cover and reset which is a losing scenario! Bad consequences will occur and hopefully their are no jumping off high places!
  • Next stop $30
  • grabbed 500 more @ $25.22. avg at $14.01
  • Got in a little late had my account frozen for some weird unresolved reason. Anyway average price paid is 24.75. From my research I can only assume this stock should hit $30-45? Just my opinion, any thoughts? Did I get in too late?